Intelligence Feed event · Credit · 2026-09-25

    ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq

    Question

    ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq

    Direct answer

    ADARx Pharmaceuticals priced an upsized initial public offering of 26.25 million common shares at $17.00 per share, generating $446.3 million in gross proceeds. The stock debuts on Nasdaq on September 25, 2026 under ticker ADRX. The upsized transaction signals resilient institutional appetite for late-stage RNA interference and siRNA therapeutic platforms despite a volatile macro rates backdrop.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-25
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq”, revision 1, evidence through 2026-09-25. https://marketontology.com/market-events/2026-09-25/adarx-pharma-prices-upsized-446-3m-ipo-at-17-on-nasdaq-c0ef0c

    CREDIT
    ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq
    ADARx Pharmaceuticals priced an upsized initial public offering of 26.25 million common shares at $17.00 per share, generating $446.3 million in gross proceeds. The stock debuts on Nasdaq on September 25, 2026 under ticker ADRX. The upsized transaction signals resilient institutional appetite for late-stage RNA interference and siRNA therapeutic platforms despite a volatile macro rates backdrop.
    ADRXXBI
    Impact
    73
    SEP 25
    SIG
    92%
    ADRXXBI
    ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq
    ADARx Pharmaceuticals priced an upsized initial public offering of 26.25 million common shares at $17.00 per share, generating $446.3 million in gross proceeds. The stock debuts on Nasdaq on September 25, 2026 under ticker ADRX. The upsized transaction signals resilient institutional appetite for late-stage RNA interference and siRNA therapeutic platforms despite a volatile macro rates backdrop.
    → A successful $446.3M equity capital raise provides multi-year clinical trial runway for ADARx's late-stage siRNA drug pipeline.
    Impact
    ADARx Pharmaceuticals priced an upsized initial public offering of 26.25 million common shares at $17.00 per share, generating $446.3 million in gross proceeds. The stock debuts on Nasdaq on September 25, 2026 under ticker ADRX. The upsized transaction signals resilient institutional appetite for late-stage RNA interference and siRNA therapeutic platforms despite a volatile macro rates backdrop.
    Affected
    ADRXXBI
    Transmission
    A successful $446.3M equity capital raise provides multi-year clinical trial runway for ADARx's late-stage siRNA drug pipeline.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ADRXinitial market trading liquidity following upsized primary offeringUpintradayPriced 26.25M shares at $17.00, raising $446.3M in gross proceeds.
    XBIbiotech primary equity issuance sentimentUp1-5dUpsized IPO pricing reflects sustained primary market demand for clinical-stage biotech.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XBIUpdisagreed155.03 2026-09-25+1.02%-0.39%Pending
    ADRXUpdisagreed19.35 2026-09-25+3.82%-5.68%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month